Search | Clinical Trials Finder

Conditions: Single Sided Deafness, Conductive Hearing Loss
Interventions: SoundBite Hearing System; Device
Lead sponsor: Sonitus Medical Inc; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 7
States / cities: Phoenix, Arizona • La Jolla, California • Newport Beach, California + 4 more

Conditions: Macular Edema Associated With Diabetes Mellitus
Interventions: Standard of Care, Macugen; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 317 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 28
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 24 more

Conditions: Non-small Cell Lung Cancer
Interventions: IPI-504, Everolimus; Drug
Lead sponsor: Infinity Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 5
States / cities: Aurora, Colorado • Tampa, Florida • Boston, Massachusetts + 1 more

Conditions: RSV Infection
Interventions: Obeldesivir, Obeldesivir Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: Up to 5 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 41
States / cities: Birmingham, Alabama • Oneonta, Alabama • Phoenix, Arizona + 33 more

Conditions: Melanoma
Interventions: MAGE-A3 ASCI injections without Poly IC:LC, MAGE-A3 ASCI injections with Poly IC:LC; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Chronic Spontaneous Urticaria
Interventions: CDX-0159, Normal Saline; Drug
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 13
States / cities: Birmingham, Alabama • Gilbert, Arizona • Sarasota, Florida + 10 more

Conditions: Atrial Fibrillation (AF)
Interventions: Pulmonary Vein Isolation, vMap® + Pulmonary Vein Isolation; Procedure · Device
Lead sponsor: Vektor Medical; Industry
Eligibility: 22 Years and older
Enrollment: 423 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 12
States / cities: Jonesboro, Arkansas • Clearwater, Florida • Jacksonville, Florida + 9 more

Conditions: Recurrent Mycosis Fungoides and Sezary Syndrome, Refractory Mycosis Fungoides and Sezary Syndrome, Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IVA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v7
Interventions: Laboratory Biomarker Analysis, Pembrolizumab; Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 8
States / cities: Palo Alto, California • New Haven, Connecticut • Tampa, Florida + 5 more

Conditions: Generalized Myasthenia Gravis
Interventions: ALXN1720, Placebo; Combination Product
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 23
States / cities: Orange, California • Fort Collins, Colorado • Washington D.C., District of Columbia + 20 more

Conditions: Hot Flashes
Interventions: Fezolinetant, placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 501 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 65
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 53 more

Conditions: End-Stage Renal Disease, Kidney Failure, Chronic
Interventions: MK-2060; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Hepatitis C
Interventions: TMC435, PSI-7977 (GS7977), Ribavirin; Drug
Lead sponsor: Janssen R&D Ireland; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 22
States / cities: Hoover, Alabama • Bakersfield, California • La Jolla, California + 19 more

Conditions: Sarcoma, Soft Tissue Sarcoma, Bone Sarcoma, Bone Metastases, Venous Thromboembolism, Hematoma, Anticoagulant-induced Bleeding
Interventions: Aspirin 325mg, Enoxaparin 40Mg/0.4mL Prefilled Syringe; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 2,868 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 10
States / cities: Los Angeles, California • Tampa, Florida • New Orleans, Louisiana + 5 more

Conditions: Post-traumatic Stress Disorder, PTSD
Interventions: Placebo, Brexpiprazole; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 417 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 22
States / cities: Los Angeles, California • Riverside, California • San Diego, California + 17 more

Conditions: Axial Spondyloarthritis
Interventions: Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg, Golimumab 50 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 347 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 11
States / cities: Peoria, Arizona • St. Petersburg, Florida • Tampa, Florida + 8 more

Conditions: Psoriasis, Plaque Psoriasis
Interventions: EDP1815, Placebo; Drug
Lead sponsor: Evelo Biosciences, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 8
States / cities: Santa Rosa, California • Orlando, Florida • St. Petersburg, Florida + 5 more

Conditions: Advanced NET of GI Origin, Advanced NET of Lung Origin, Neuroendocrine Tumors
Interventions: Everolimus, Placebo, Best suportive care (BSC); Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 17
States / cities: La Jolla, California • Los Angeles, California • Aurora, Colorado + 11 more

Conditions: Lung Neoplasms
Interventions: CP-547,632; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 20
States / cities: Greenbrae, California • San Mateo, California • San Pablo, California + 13 more

Conditions: Cancer, Cancer Screening Patients, Patient Volunteers
Interventions: First Questionnaire, Health History, Second Questionnaire; Behavioral
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 30 Years and older
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Enterovirus, Rhinovirus
Interventions: Nitazoxanide, Placebo; Drug
Lead sponsor: Romark Laboratories L.C.; Industry
Eligibility: 12 Years and older
Enrollment: 1,756 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 43
States / cities: Birmingham, Alabama • Pelham, Alabama • Hot Springs, Arkansas + 36 more

Conditions: Alzheimer Disease
Interventions: Gantenerumab, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 975 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 47
States / cities: Phoenix, Arizona • Sun City, Arizona • Fayetteville, Arkansas + 39 more

Conditions: Pediatric Epileptic Syndrome, Partial-onset Seizures
Interventions: Perampanel Oral Suspension, Perampanel Tablet; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 1 Month to 18 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 22
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 19 more

Conditions: Atopic Dermatitis, Eczema, Atopic
Interventions: ALX-101 Gel 1.5% and ALX-101 Gel Vehicle, ALX-101 Gel 5% and ALX-101 Gel Vehicle; Drug
Lead sponsor: Ralexar Therapeutics, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 35
States / cities: Anniston, Alabama • Birmingham, Alabama • Laguna Hills, California + 28 more

Conditions: Multi-Level Degenerative Lumbosacral Spinal Conditions
Interventions: Infuse Bone Graft, Medtronic DBM; Device
Lead sponsor: Medtronic Spinal and Biologics; Industry
Eligibility: 21 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 17
States / cities: Sacramento, California • Durango, Colorado • Vail, Colorado + 13 more

Search by objective public record fields.

SoundBite Hearing System 24 Month Multi Site Patient Use Study

A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.

Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer

Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection

Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC

A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

Artificial Intelligence Mapping and Ablation of Non-Pulmonary Vein Electrical Drivers of AF Study

Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome

Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis

A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2

MK-2060 and Clopidogrel Co-administration Safety and Tolerability Study in Participants With End-Stage Renal Disease (ESRD) (MK-2060-008)

A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients

LMWH vs Aspirin for VTE Prophylaxis in Orthopaedic Oncology

Brexpiprazole as an Adjunctive Treatment to Paroxetine or Sertraline in Adult Patients Suffering From Post-traumatic Stress Disorder (PTSD)

A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis

A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis

Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)

A Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 Given In Combination With Chemotherapy

Evaluation of Patient Functionality and Utility of Web-Based Personal Health History and Risk Assess

Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection

Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy

A Study in Subjects With Moderate Atopic Dermatitis

A Study of Infuse® Bone Graft With Mastergraft® Strip and Posterior Fixation for Posterolateral Fusion (PLF) Treatment of Multi-Level Degenerative Lumbosacral Spinal Conditions